Literature DB >> 26111072

MELD-Na as a prognostic indicator of 30- and 90-day mortality in patients with end-stage liver disease after creation of transjugular intrahepatic portosystemic shunt.

Rezwan Ahmed1, Prasanna Santhanam, Yaser Rayyan.   

Abstract

Previous studies have shown that the Model for End-Stage Liver Disease (MELD) score is superior to other liver disease scoring systems to establish optimal candidates for transjugular intrahepatic portosystemic shunt (TIPS) procedure and liver transplantation. Our aim was to compare MELD-Na score with MELD score as a predictor of 30-day as well as 90-day mortality for individuals with end-stage liver disease (ESLD) after creation of TIPS. We performed a chart review on cirrhotic patients who underwent TIPS procedure and documented presence and severity of ascites and hepatic encephalopathy, patient laboratory values, and results from TIPS procedures. We compared continuous variables by Student's t-test for independent samples and categorical variables by χ-test(s). In non-normal distributions, a nonparametric test was used. We performed a logistic regression to determine the effects of several variables and analyzed variable predictors of likelihood of death within 30 and 90 days of TIPS procedure. Of the six predictor variables, only MELD-Na score was a statistically significant predictor of 30- and 90-day mortality following TIPS procedure for ESLD (P=0.028). For each one point increase in MELD-Na score, the odds of death increased by 1.15 times [95% confidence interval (1.02-1.30), P=0.28]. Since hyponatremia may be associated with poor prognostic features of overall health, its incorporation into the MELD scoring system to predict mortality in ESLD after creation of TIPS serves a useful purpose. Our single-center experience suggests that the MELD-Na score is the most effective predictor of survival after TIPS creation.

Entities:  

Mesh:

Year:  2015        PMID: 26111072     DOI: 10.1097/MEG.0000000000000412

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  5 in total

1.  Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma.

Authors:  Ying-Fen Hong; Zhan-Hong Chen; Xiao-Kun Ma; Xing Li; Dong-Hao Wu; Jie Chen; Min Dong; Li Wei; Tian-Tian Wang; Dan-Yun Ruan; Ze-Xiao Lin; Jing-Yun Wen; Qu Lin; Chang-Chang Jia; Xiang-Yuan Wu
Journal:  Tumour Biol       Date:  2015-11-11

2.  Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt.

Authors:  Dongmei Zhao; Guobing Zhang; Mingquan Wang; Chaoxue Zhang; Jiabin Li
Journal:  Clin Mol Hepatol       Date:  2019-03-22

3.  Prognostic Value of the CLIF-C AD Score in Patients With Implantation of Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Lukas Sturm; Michael Praktiknjo; Dominik Bettinger; Jan P Huber; Lara Volkwein; Arthur Schmidt; Rafael Kaeser; Johannes Chang; Christian Jansen; Carsten Meyer; Daniel Thomas; Robert Thimme; Jonel Trebicka; Michael Schultheiß
Journal:  Hepatol Commun       Date:  2021-01-05

4.  Prediction of Patient Survival with Psoas Muscle Density Following Transjugular Intrahepatic Portosystemic Shunts: A Retrospective Cohort Study.

Authors:  Biyu Zhang; Weimin Cai; Feng Gao; Xinran Lin; Ting Qian; Kaier Gu; Bingxin Song; Tanzhou Chen
Journal:  Med Sci Monit       Date:  2022-01-15

5.  Outcomes After TIPS for Ascites and Variceal Bleeding in a Contemporary Era-An ALTA Group Study.

Authors:  Justin Richard Boike; Nikhilesh Ray Mazumder; Kanti Pallav Kolli; Jin Ge; Margarita German; Nathaniel Jest; Giuseppe Morelli; Erin Spengler; Adnan Said; Jennifer C Lai; Archita P Desai; Thomas Couri; Sonali Paul; Catherine Frenette; Elizabeth C Verna; Usman Rahim; Aparna Goel; Dyanna Gregory; Bartley Thornburg; Lisa B VanWagner
Journal:  Am J Gastroenterol       Date:  2021-10-01       Impact factor: 12.045

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.